LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a mix of positive and cautious elements. Strong early sales of VIZZ and positive initial feedback are promising, but management's reluctance to provide detailed guidance or conversion rates tempers enthusiasm. While the marketing strategy and spokesperson choice are well-received, the lack of specific prescription trends and financial guidance suggests uncertainty. The neutral sentiment reflects this balance of optimism and caution.
Key Financial Performance
Cash Position Current total cash position is approximately $324 million, up from the previous quarter due to a direct placement raising more than $123 million. This increase is attributed to a single large institutional investor's interest, which is seen as a validation of the company's launch strategy.
License Revenue Total license revenue for the third quarter was $12.5 million, which includes $10 million from two $5 million milestones under the agreement with Corxel Pharmaceuticals in China and $2.5 million upfront payment from Laboratoires Thea for commercialization rights in Canada.
Operating Expenses Total operating expenses for Q3 2025 increased to $31.4 million, a 44% increase over Q2. SG&A expenses rose to $27.6 million, up 116% from the previous quarter, driven by commercial headcount and pre-commercial marketing activities. R&D expenses decreased to $3.8 million, down 58% from Q2, as pre-approval manufacturing efforts were completed.
Net Loss Net loss for Q3 2025 was $16.7 million, or $0.59 per share, compared to $10.2 million, or $0.38 per share, in Q3 2024. The increase in net loss is attributed to higher SG&A expenses related to the commercial launch of VIZZ.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA approval and launch of VIZZ: VIZZ, an aceclidine-based eye drop for presbyopia, was FDA approved in July 2025 and launched in the U.S. in October 2025. It is the first product of its kind, with over 5,000 prescriptions filled in October and 2,500 doctors prescribing it.
Product differentiation and feedback: VIZZ is noted for its rapid improvement in vision, long duration, and minimal side effects. It is the only pupil-selective treatment for presbyopia, with transient side effects like stinging and redness.
Direct-to-consumer campaign: A campaign featuring Sarah Jessica Parker as spokesperson will launch in Q1 2026 to drive consumer awareness and demand.
Market size and opportunity: Presbyopia affects 128 million people in the U.S., a market larger than other vision conditions combined. VIZZ aims to establish itself as the standard of care.
Ex-U.S. partnerships: LENZ has partnerships in China and Canada, with $12.5 million in license revenue recorded in Q3 2025. Agreements include milestones and royalties.
Financial performance: LENZ raised $123 million in October, bringing its cash position to $324 million. Q3 operating expenses were $31.4 million, with a focus on commercial activities.
Sales and distribution: 70,000 samples of VIZZ were distributed to 7,000 offices, achieving 90% awareness among eye care professionals within weeks of launch.
Strategic focus on presbyopia: LENZ is positioning VIZZ as a category-defining product, focusing on awareness, confidence, and willingness to prescribe among eye care professionals.
Consumer engagement strategy: The upcoming direct-to-consumer campaign aims to establish VIZZ as a lifestyle product, leveraging its unique benefits and celebrity endorsement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Adverse Events (AEs): Instances of stinging and transient hyperemia (redness) were reported more frequently than initially expected. While these effects are short-lived and fade quickly, they could impact patient satisfaction and adoption rates.
Tachyphylaxis Phase: Doctors and patients report that side effects like redness and stinging lessen over time, but initial discomfort could deter early adoption or repeat prescriptions.
Commercial Launch Challenges: The company is in the early stages of its commercial launch, and success depends on building awareness, confidence, and willingness to prescribe among eye care professionals. Any missteps in this phase could hinder long-term adoption.
Direct-to-Consumer (DTC) Campaign Risks: The success of the upcoming DTC campaign in 2026 is critical for consumer adoption. Failure to resonate with the target audience or ineffective marketing could impact sales.
Financial Risks: The company has significantly increased its SG&A expenses to support the launch, which could strain financial resources if sales do not meet expectations. Additionally, reliance on a single large institutional investor for recent funding could pose risks if future funding needs arise.
Regulatory and Market Risks: The company is dependent on regulatory approvals and market acceptance in ex-U.S. territories. Any delays or failures in these areas could impact revenue projections.
Competitive Pressures: Although VIZZ is positioned as a category of one, competitive pressures from existing or new entrants in the ophthalmology space could impact market share.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Direct-to-Consumer Campaign Launch: LENZ plans to initiate a direct-to-consumer (DTC) campaign in Q1 2026, with Sarah Jessica Parker as the spokesperson. This campaign aims to drive consumer awareness and demand for VIZZ, positioning it as a category-leading product.
Financial Position and Cash Runway: The company raised $123 million in October 2025, bringing its total cash position to $324 million. This cash is expected to fund operations until the company achieves post-launch positive operating cash flow.
Ex-U.S. Strategic Partnerships: LENZ has made progress with international partnerships, including a $2.5 million upfront payment from Laboratoires Thea for commercialization rights in Canada and $10 million in milestone payments from Corxel Pharmaceuticals in China. Additional regulatory and commercial milestones are expected.
Market Adoption and Awareness: By the end of October 2025, 90% of eye care professionals were aware of VIZZ, and over 2,500 doctors had prescribed it, with 40% writing multiple prescriptions. The company distributed 70,000 samples to 7,000 offices to build confidence and willingness to prescribe.
Product Differentiation and Feedback: VIZZ is positioned as a unique, category-leading product for presbyopia, offering rapid onset and long duration of effect. Early feedback from doctors and patients has been positive, with minimal side effects reported.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What approaches is the commercial team taking to set expectations for the VIZZ profile, and how are they addressing patient concerns about efficacy versus side effects?
A:The commercial team is focusing on setting expectations by highlighting the immediate vision improvement within 10-15 minutes of using VIZZ. They are addressing side effects like transient redness and stinging by educating patients and doctors, emphasizing that these effects typically subside after a few days. Sales representatives are conducting 13,000 calls every 4 weeks, and speaker bureau events have been updated to include real-life photos to contextualize the transient nature of redness.
Q:Can you disclose the week-over-week cadence of prescriptions for October and provide feedback on whether patients are opting for 3-month versus 1-month treatments?
A:Management stated it is too early to share trends in prescription data. They noted that 5,000 scripts have been filled, but full product availability in retail pharmacies will not occur until mid-November. Some patients are opting for 3-month treatments, but management did not provide specific percentages, citing the need for a full quarter of data.
Q:How does the early launch of VIZZ compare to VUITY, and what is the conversion rate from samples to paid scripts?
A:Management is encouraged by the early launch of VIZZ, noting that the 5,000 filled scripts compare well to VUITY's early days. They are not focused on sample-to-paid script conversion rates at this stage, as the priority is ensuring widespread sample availability. Samples are being used by doctors and staff to familiarize themselves with the product.
Q:Why was Sarah Jessica Parker chosen as the spokesperson for VIZZ, and has she used the product?
A:Sarah Jessica Parker was chosen for her authenticity, alignment with the target demographic (female, metropolitan areas), and her elevated brand image. She has used and liked the product, which was a requirement for her selection.
Q:What is the expectation for sampling and conversion rates among eye care professionals (ECPs)?
A:Management aims to provide samples to all interested ECP offices. Currently, 7,000 offices have been sampled, and 2,500 ECPs are prescribing. The focus is on targeted doctors, but mechanisms are in place to support non-targeted doctors expressing interest. Sampling will be ongoing to encourage patient trials.
Q:What are the demographics of the initial VIZZ users, and is pricing a concern?
A:Initial users are predominantly 45-65 years old, female, and located in metropolitan areas. Management has not observed significant pushback on pricing, with feedback focusing on the product's efficacy and quick results.
Q:What is the significance of the distance vision benefit observed with VIZZ, and will there be a study to add this to the label?
A:The distance vision benefit is an encouraging anecdotal observation, with 41% of Phase III participants showing improvement. While not critical to VIZZ's success as a near vision improvement drug, management is considering a study to explore this benefit further.
Q:How is the sales force targeting optometrists versus ophthalmologists, and will this strategy change?
A:The sales force is targeting 80% optometrists and 20% ophthalmologists, reflecting the early prescriber base of VUITY. Management does not anticipate changes to this mix in the near term.
Q:What mechanisms are in place to support non-targeted doctors expressing interest in VIZZ?
A:An inside sales force of 10 people is available to connect with non-targeted doctors, and samples can be shipped to them. Sales representatives may also visit non-targeted offices located near targeted ones.
Q:What is the average time to fill prescriptions through e-pharmacy and retail pharmacies?
A:E-pharmacy prescriptions are typically filled within 2-5 days, with priority shipping available for faster delivery. Retail pharmacies have similar timelines.
Q:What is the barrier to getting all target doctors to opt into the 'find a doctor' tool on vizz.com?
A:The opt-in process requires doctors to actively engage, have samples, and understand the product. Management views the current 9,000 opt-ins as a positive indicator of enthusiasm and expects this number to grow as the launch progresses.
Q:What is the SG&A run rate for Q4, and what is the expected step-up in spend for the DTC campaign in Q1 2026?
A:SG&A increased from $12.8 million in Q2 to $27.6 million in Q3, with a similar trend expected in Q4. For 2026, commercial spend is projected at $80-100 million annually, including the DTC campaign, with an additional $20-25 million for G&A.
Q:Review of Unclear Management Responses
A:Management avoided providing specific week-over-week prescription trends for October, citing the early stage of the launch and incomplete retail pharmacy availability. They also did not disclose the percentage of patients opting for 3-month treatments, stating that more meaningful data would be available after a full quarter. Additionally, they did not provide detailed conversion rates from samples to paid scripts, emphasizing that this is not a focus at this stage of the launch.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ATM
DTC campaign
FDA approval
Olsson Chief
SJP
adoption
adult
awareness confidence
balance sheet
belief
care awareness
care community
commercialization agreement
confidence product
consumer phase
doctor confidence
duration
efficacy doctor
enthusiasm
experience confidence
feedback doctor
field
forma
license payment
objective
office
patient experience
patient work
payment milestone
period FDA
phase consumer
phase launch
placement
product willingness
redness
speaker
staff
start launch
world
LENZ Transcript
LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
Unknown5-11
The earnings call presents a mixed picture: strong early signals from consumer campaigns and a large market potential are positive, but the company's financials show a significant net loss and increased expenses. The Q&A highlights management's focus on consumer awareness and product efficacy, yet lacks clarity on some critical operational details. The absence of R&D spending could be concerning. Without clear guidance or a strong financial performance, the stock price is likely to remain stable over the next two weeks, resulting in a neutral sentiment.
LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call indicates a significant net loss increase, with a widening loss per share, which is a negative sign. Despite some positive signals in product adoption and marketing strategies, the lack of specific data on important metrics and the deferral of detailed refill metrics suggest uncertainties. The management's optimistic guidance on DTC efforts and sales force expansion is tempered by the potential delay in seeing results. Overall, the negative financial performance and uncertainties in execution outweigh the positive aspects, leading to a likely negative stock price reaction.
LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-4
LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call summary indicates a mix of positive and cautious elements. Strong early sales of VIZZ and positive initial feedback are promising, but management's reluctance to provide detailed guidance or conversion rates tempers enthusiasm. While the marketing strategy and spokesperson choice are well-received, the lack of specific prescription trends and financial guidance suggests uncertainty. The neutral sentiment reflects this balance of optimism and caution.
LENZ Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
